These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 30288546)

  • 1. Trichostatin A, a histone deacetylase inhibitor, induces synergistic cytotoxicity with chemotherapy via suppression of Raf/MEK/ERK pathway in urothelial carcinoma.
    Lin WC; Hsu FS; Kuo KL; Liu SH; Shun CT; Shi CS; Chang HC; Tsai YC; Lin MC; Wu JT; Kuo Y; Chow PM; Liao SM; Yang SP; Hong JY; Huang KH
    J Mol Med (Berl); 2018 Dec; 96(12):1307-1318. PubMed ID: 30288546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone Deacetylase Inhibitor, Trichostatin A, Synergistically Enhances Paclitaxel-Induced Cytotoxicity in Urothelial Carcinoma Cells by Suppressing the ERK Pathway.
    Hsu FS; Wu JT; Lin JY; Yang SP; Kuo KL; Lin WC; Shi CS; Chow PM; Liao SM; Pan CI; Hong JY; Chang HC; Huang KH
    Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30866433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of caspase mediated apoptosis and down-regulation of nuclear factor-κB and Akt signaling are involved in the synergistic antitumor effect of gemcitabine and the histone deacetylase inhibitor trichostatin A in human bladder cancer cells.
    Jeon HG; Yoon CY; Yu JH; Park MJ; Lee JE; Jeong SJ; Hong SK; Byun SS; Lee SE
    J Urol; 2011 Nov; 186(5):2084-93. PubMed ID: 21944112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylase inhibitor trichostatin A resensitizes gemcitabine resistant urothelial carcinoma cells via suppression of TG-interacting factor.
    Yeh BW; Li WM; Li CC; Kang WY; Huang CN; Hour TC; Liu ZM; Wu WJ; Huang HS
    Toxicol Appl Pharmacol; 2016 Jan; 290():98-106. PubMed ID: 26589485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status.
    Chao MW; Chang LH; Tu HJ; Chang CD; Lai MJ; Chen YY; Liou JP; Teng CM; Pan SL
    Clin Epigenetics; 2019 May; 11(1):85. PubMed ID: 31142371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Panobinostat synergistically enhances the cytotoxic effects of cisplatin, doxorubicin or etoposide on high-risk neuroblastoma cells.
    Wang G; Edwards H; Caldwell JT; Buck SA; Qing WY; Taub JW; Ge Y; Wang Z
    PLoS One; 2013; 8(9):e76662. PubMed ID: 24098799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metformin synergistically enhances antitumor activity of histone deacetylase inhibitor trichostatin a against osteosarcoma cell line.
    Duo J; Ma Y; Wang G; Han X; Zhang C
    DNA Cell Biol; 2013 Apr; 32(4):156-64. PubMed ID: 23451817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The heat shock protein 90 inhibitor SNX5422 has a synergistic activity with histone deacetylase inhibitors in induction of death of anaplastic thyroid carcinoma cells.
    Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
    Endocrine; 2016 Feb; 51(2):274-82. PubMed ID: 26219406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Whole-transcriptomic Profile of SK-MEL-3 Melanoma Cells Treated with the Histone Deacetylase Inhibitor: Trichostatin A.
    Mazzio EA; Soliman KFA
    Cancer Genomics Proteomics; 2018; 15(5):349-364. PubMed ID: 30194076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of the ERK pathway enhances the therapeutic efficacy of the histone deacetylase inhibitor MS-275 in human tumor xenograft models.
    Sakamoto T; Ozaki K; Fujio K; Kajikawa SH; Uesato S; Watanabe K; Tanimura S; Koji T; Kohno M
    Biochem Biophys Res Commun; 2013 Apr; 433(4):456-62. PubMed ID: 23501104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correction to: Trichostatin A, a histone deacetylase inhibitor, induces synergistic cytotoxicity with chemotherapy via suppression of Raf/MEK/ERK pathway in urothelial carcinoma.
    Lin WC; Hsu FS; Kuo KL; Liu SH; Shun CT; Shi CS; Chang HC; Tsai YC; Lin MC; Wu JT; Kuo Y; Chow PM; Liao SM; Yang SP; Hong JY; Huang KH
    J Mol Med (Berl); 2019 Mar; 97(3):435-436. PubMed ID: 30741319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Synergistic cytotoxicity effect of histone deacetylase inhibitor combined with paclitaxel on lung cancer cell lines and its mechanism].
    Zhang D; Liu CT; Yu XD; Liu Y
    Ai Zheng; 2009 Dec; 28(12):1270-6. PubMed ID: 19958621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subamolide A, a component isolated from Cinnamomum subavenium, induces apoptosis mediated by mitochondria-dependent, p53 and ERK1/2 pathways in human urothelial carcinoma cell line NTUB1.
    Liu CH; Chen CY; Huang AM; Li JH
    J Ethnopharmacol; 2011 Sep; 137(1):503-11. PubMed ID: 21708241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model.
    Touma SE; Goldberg JS; Moench P; Guo X; Tickoo SK; Gudas LJ; Nanus DM
    Clin Cancer Res; 2005 May; 11(9):3558-66. PubMed ID: 15867260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trichostatin A potentiates TRAIL-induced antitumor effects via inhibition of ERK/FOXM1 pathway in gastric cancer.
    Li L; Fan B; Zhang LH; Xing XF; Cheng XJ; Wang XH; Guo T; Du H; Wen XZ; Ji JF
    Tumour Biol; 2016 Aug; 37(8):10269-78. PubMed ID: 26831669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different effect of protein kinase B/Akt and extracellular signal-regulated kinase inhibition on trichostatin A-induced apoptosis in epithelial ovarian carcinoma cell lines.
    Jang ER; Kim YJ; Myung SC; Kim W; Lee CS
    Mol Cell Biochem; 2011 Jul; 353(1-2):1-11. PubMed ID: 21380726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of trichostatin A on Burkitt's lymphoma cells: Inhibition of EPS8 activity through Phospho-Erk1/2 pathway.
    Sun P; Zhou X; He Y; Liu H; Wang Y; Chen Y; Li M; He Y; Li G; Li Y
    Biochem Biophys Res Commun; 2018 Mar; 497(4):990-996. PubMed ID: 29462617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New synergistic combination therapy approaches with HDAC inhibitor quisinostat, cisplatin or PARP inhibitor talazoparib for urothelial carcinoma.
    Meneceur S; De Vos CE; Petzsch P; Köhrer K; Niegisch G; Hoffmann MJ
    J Cell Mol Med; 2024 May; 28(9):e18342. PubMed ID: 38693852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase inhibitor, trichostatin A, increases the chemosensitivity of anticancer drugs in gastric cancer cell lines.
    Zhang X; Yashiro M; Ren J; Hirakawa K
    Oncol Rep; 2006 Sep; 16(3):563-8. PubMed ID: 16865256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trichostatin A promotes esophageal squamous cell carcinoma cell migration and EMT through BRD4/ERK1/2-dependent pathway.
    Liu D; Liu Y; Qi B; Gu C; Huo S; Zhao B
    Cancer Med; 2021 Aug; 10(15):5235-5245. PubMed ID: 34160902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.